Cefdinir: Difference between revisions
No edit summary |
(→General: edited dosage forms, strengths, routes of administration) |
||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: Third generation [[cephalosporin]] | *Type: Third generation [[cephalosporin]] | ||
*Dosage Forms: 300mg oral | *Dosage Forms: capsule, oral suspension | ||
*Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL | |||
*Routes of Administration: PO | |||
*Common Trade Names: Omnicef | *Common Trade Names: Omnicef | ||
Revision as of 00:55, 12 October 2017
General
- Type: Third generation cephalosporin
- Dosage Forms: capsule, oral suspension
- Dosage Strengths: capsule: 300mg; oral suspension: 125mg/5mL, 250mg/5mL
- Routes of Administration: PO
- Common Trade Names: Omnicef
Adult Dosing
- 600mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis
Pediatric Dosing
- 14mg/kg/d PO divided q12-24hrs x10 days, max of 600mg/day
Special Populations
- Pregnancy Rating: B
- Lactation: Probably safe
- Renal Dosing
- Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
- Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
- Hepatic dosing not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Stool discoloration which is guiac negative and returns to normal color after cessation
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014
